Argent Biopharma Limited has released a press release.
Half Year Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Corporate Update - Board Change
- Placing to Raise US$4,500,000
- Trading Halt
- ASX Listing Update
- Placing to Raise A$200,000
Later from Argent Biopharma
- Strategic Manufacturing Partnership with ECCPharm Limited
- Exclusive Agreement for Malta Manufacturing Facility
- Argent BioPharma Expands Pipeline with Promising Drug CimetrA®
- CimetrA Phase IIb Clinical Trial Results
- CannEpil Receives Approval for Prescription in Germany
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma